Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $127000.0.

  • Lineage Cell Therapeutics' Receivables - Net fell 6864.2% to $127000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $127000.0, marking a year-over-year decrease of 6864.2%. This contributed to the annual value of $638000.0 for FY2024, which is 1436.24% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Receivables - Net of $127000.0 as of Q3 2025, which was down 6864.2% from $256000.0 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Receivables - Net high stood at $50.8 million for Q4 2021, and its period low was $77000.0 during Q1 2024.
  • For the 5-year period, Lineage Cell Therapeutics' Receivables - Net averaged around $3.0 million, with its median value being $326000.0 (2021).
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Receivables - Net was 127090000.0% (2021), while the steepest drop was 9954.57% (2021).
  • Over the past 5 years, Lineage Cell Therapeutics' Receivables - Net (Quarter) stood at $50.8 million in 2021, then plummeted by 99.41% to $300000.0 in 2022, then surged by 148.33% to $745000.0 in 2023, then fell by 14.36% to $638000.0 in 2024, then plummeted by 80.09% to $127000.0 in 2025.
  • Its Receivables - Net stands at $127000.0 for Q3 2025, versus $256000.0 for Q2 2025 and $213000.0 for Q1 2025.